P
Pascal Cohen
Researcher at University of Paris
Publications - 172
Citations - 14187
Pascal Cohen is an academic researcher from University of Paris. The author has contributed to research in topics: Vasculitis & Granulomatosis with polyangiitis. The author has an hindex of 46, co-authored 156 publications receiving 12462 citations. Previous affiliations of Pascal Cohen include Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Churg-Strauss Syndrome. Clinical Study and Long-Term Follow-Up of 96 Patients
TL;DR: The long-term prognosis of CSS is good and does not differ from that of polyarteritis nodosa, although most patients need low doses of oral corticosteroids for persistent asthma, even many years after clinical recovery from vasculitis.
Journal ArticleDOI
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.
Loïc Guillevin,François Lhote,M. Gayraud,Pascal Cohen,Bernard Jarrousse,Olivier Lortholary,Nadine Thibult,Philippe Casassus +7 more
TL;DR: It is concluded that an initial assessment of PAN or CSS severity enables outcome and mortality to be predicted and the FFS is a good predictor of death and can be used to help the clinician choose the most adequate treatment.
Journal ArticleDOI
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loïc Guillevin,Christian Pagnoux,Alexandre Karras,Chahéra Khouatra,Olivier Aumaître,Pascal Cohen,François Maurier,Olivier Decaux,Jacques Ninet,P. Gobert,Thomas Quemeneur,Claire Blanchard-Delaunay,Pascal Godmer,Xavier Puéchal,Pierre-Louis Carron,Pierre-Yves Hatron,Nicolas Limal,Mohamed Hamidou,Maize Ducret,Eric Daugas,Thomas Papo,Bernard Bonnotte,Alfred Mahr,Philippe Ravaud,Luc Mouthon +24 more
TL;DR: More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine, and the frequencies of severe adverse events were similar in the two groups.
Journal ArticleDOI
Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort
Cloé Comarmond,Christian Pagnoux,Mehdi Khellaf,Jean-François Cordier,Mohamed Hamidou,Jean-François Viallard,François Maurier,Stéphane Jouneau,Boris Bienvenu,Xavier Puéchal,Olivier Aumaître,Guillaume Le Guenno,Alain Le Quellec,Ramiro Cevallos,Olivier Fain,Bertrand Godeau,Raphaèle Seror,Bertrand Dunogué,Alfred Mahr,Philippe Guilpain,Pascal Cohen,Achille Aouba,Luc Mouthon,Loïc Guillevin +23 more
TL;DR: Although EGPA relapses remain frequent, mortality has declined, at least since 1996, and multivariable analysis identified cardiomyopathy, older age, and diagnosis during or prior to 1996 as independent risk factors for death and lower eosinophil count at diagnosis as predictive of relapse.
Journal ArticleDOI
Antineutrophil Cytoplasmic Antibodies and the Churg–Strauss Syndrome
Régis Sablé-Fourtassou,Pascal Cohen,Alfred Mahr,Christian Pagnoux,Luc Mouthon,David Jayne,Daniel Engelbert Blockmans,Jean-François Cordier,Philippe Delaval,Xavier Puéchal,Dominique Lauque,Jean-François Viallard,Abdelkader Zoulim,Loïc Guillevin +13 more
TL;DR: The clinical characteristics of patients who recently received a diagnosis of the ChurgStrauss syndrome and who were included in prospective therapeutic trials organized by the French Vasculitis Study Group (FVSG) and the EUVAS were described to compare the characteristics of Patients with and without ANCA.